Entity Details

Primary name MECP2_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP51608
EntryNameMECP2_HUMAN
FullNameMethyl-CpG-binding protein 2
TaxID9606
Evidenceevidence at protein level
Length486
SequenceStatuscomplete
DateCreated1996-10-01
DateModified2021-06-02

Ontological Relatives

GenesMECP2

GO terms

Show/Hide Table
GOName
GO:0000122 negative regulation of transcription by RNA polymerase II
GO:0000792 heterochromatin
GO:0001662 behavioral fear response
GO:0001666 response to hypoxia
GO:0001964 startle response
GO:0001976 nervous system process involved in regulation of systemic arterial blood pressure
GO:0002087 regulation of respiratory gaseous exchange by nervous system process
GO:0003677 DNA binding
GO:0003682 chromatin binding
GO:0003700 DNA-binding transcription factor activity
GO:0003714 transcription corepressor activity
GO:0003723 RNA binding
GO:0003729 mRNA binding
GO:0005615 extracellular space
GO:0005634 nucleus
GO:0005654 nucleoplasm
GO:0005813 centrosome
GO:0005829 cytosol
GO:0006020 inositol metabolic process
GO:0006342 chromatin silencing
GO:0006349 regulation of gene expression by genetic imprinting
GO:0006541 glutamine metabolic process
GO:0006576 cellular biogenic amine metabolic process
GO:0007052 mitotic spindle organization
GO:0007416 synapse assembly
GO:0007585 respiratory gaseous exchange by respiratory system
GO:0007616 long-term memory
GO:0008104 protein localization
GO:0008134 transcription factor binding
GO:0008211 glucocorticoid metabolic process
GO:0008284 positive regulation of cell population proliferation
GO:0008327 methyl-CpG binding
GO:0008344 adult locomotory behavior
GO:0008542 visual learning
GO:0009791 post-embryonic development
GO:0010385 double-stranded methylated DNA binding
GO:0010629 negative regulation of gene expression
GO:0010971 positive regulation of G2/M transition of mitotic cell cycle
GO:0016358 dendrite development
GO:0016525 negative regulation of angiogenesis
GO:0016571 histone methylation
GO:0016573 histone acetylation
GO:0019230 proprioception
GO:0019233 sensory perception of pain
GO:0019904 protein domain specific binding
GO:0021549 cerebellum development
GO:0021591 ventricular system development
GO:0032048 cardiolipin metabolic process
GO:0035176 social behavior
GO:0035197 siRNA binding
GO:0042551 neuron maturation
GO:0043524 negative regulation of neuron apoptotic process
GO:0043537 negative regulation of blood vessel endothelial cell migration
GO:0045892 negative regulation of transcription, DNA-templated
GO:0045944 positive regulation of transcription by RNA polymerase II
GO:0046470 phosphatidylcholine metabolic process
GO:0047485 protein N-terminus binding
GO:0051151 negative regulation of smooth muscle cell differentiation
GO:0051707 response to other organism
GO:0060079 excitatory postsynaptic potential
GO:0060260 regulation of transcription initiation from RNA polymerase II promoter
GO:0060291 long-term synaptic potentiation
GO:0090063 positive regulation of microtubule nucleation
GO:0098794 postsynapse
GO:1900114 positive regulation of histone H3-K9 trimethylation
GO:1905643 positive regulation of DNA methylation
GO:1990841 promoter-specific chromatin binding
GO:2000820 negative regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation

Subcellular Location

Show/Hide Table
Subcellular Location
Nucleus

Domains

Show/Hide Table
DomainNameCategoryType
IPR001739 Methyl-CpG DNA bindingDomainDomain
IPR016177 DNA-binding domain superfamilyFamilyHomologous superfamily
IPR017353 Methyl-CpG binding protein MeCP2FamilyFamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
300260 OMIMMental retardation, X-linked, syndromic, Lubs type (MRXSL)A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXSL patients manifest mental retardation associated with variable features. They include swallowing dysfunction and gastroesophageal reflux with secondary recurrent respiratory infections, hypotonia, mild myopathy and characteristic facies such as downslanting palpebral fissures, hypertelorism and a short nose with a low nasal bridge. The disease is caused by variants affecting the gene represented in this entry. Increased dosage of MECP2 due to gene duplication appears to be responsible for the mental retardation phenotype.
300055 OMIMMental retardation, X-linked, syndromic, 13 (MRXS13)A disorder characterized by significantly below average general intellectual functioning associated with impairments in adaptive behavior and manifested during the developmental period. MRXS13 patients manifest mental retardation associated with other variable features such as spasticity, episodes of manic depressive psychosis, increased tone and macroorchidism. The disease is caused by variants affecting the gene represented in this entry.
300673 OMIMEncephalopathy, neonatal severe, due to MECP2 mutations (ENS-MECP2)A neurodevelopmental disorder characterized by severe neonatal encephalopathy, developmental delay, mental retardation, microcephaly, seizures. Additional features include respiratory insufficiency and central hypoventilation, gastroesophageal reflux, axial hypotonia, hyperreflexia and dyskinetic movements. The disease is caused by variants affecting the gene represented in this entry. The MECP2 gene is mutated in Rett syndrome, a severe neurodevelopmental disorder that almost always occurs in females. Although it was first thought that MECP2 mutations causing Rett syndrome were lethal in males, later reports identified a severe neonatal encephalopathy in surviving male sibs of patients with Rett syndrome. Additional reports have confirmed a severe phenotype in males with Rett syndrome-associated MECP2 mutations.
312750 OMIMRett syndrome (RTT)An X-linked dominant neurodevelopmental disorder, and one of the most common causes of mental retardation in females. Patients appear to develop normally until 6 to 18 months of age, then gradually lose speech and purposeful hand movements, and develop microcephaly, seizures, autism, ataxia, mental retardation and stereotypic hand movements. After initial regression, the condition stabilizes and patients usually survive into adulthood. The disease is caused by variants affecting the gene represented in this entry.
300496 OMIMAutism, X-linked 3 (AUTSX3)A complex multifactorial, pervasive developmental disorder characterized by impairments in reciprocal social interaction and communication, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by 3 years of age. Most individuals with autism also manifest moderate mental retardation. The disease may be caused by variants affecting the gene represented in this entry.
105830 OMIMAngelman syndrome (AS)A neurodevelopmental disorder characterized by severe motor and intellectual retardation, ataxia, frequent jerky limb movements and flapping of the arms and hands, hypotonia, seizures, absence of speech, frequent smiling and episodes of paroxysmal laughter, open-mouthed expression revealing the tongue. The disease may be caused by variants affecting the gene represented in this entry.

Interactions

78 interactions

InteractorPartnerSourcesPublicationsLink
MECP2_HUMANSMCA2_HUMANBioGRID, HPRD, IntAct15696166 20093853 details
MECP2_HUMANHIPK2_HUMANBioGRID, MINT19820693 details
MECP2_HUMANSOX18_HUMANBioGRID, IntAct21988832 details
MECP2_HUMANTBL1R_HUMANBioGRID, DIP23770565 28348241 details
MECP2_HUMANSIN3A_HUMANBioGRID, DIP, HPRD10773092 11441023 14593184 15322089 22615490 23770565 9620779 9620804 details
MECP2_HUMANHSPB1_HUMANIntAct32814053 details
MECP2_HUMANAP2B1_HUMANIntAct32814053 details
MECP2_HUMANRASF5_HUMANIntAct32814053 details
MECP2_HUMANAB17C_HUMANIntAct32814053 details
MECP2_HUMANOTU7B_HUMANIntAct32814053 details
MECP2_HUMANOTUB1_HUMANIntAct32814053 details
MECP2_HUMANASB3_HUMANIntAct32814053 details
MECP2_HUMANKLH20_HUMANIntAct32814053 details
MECP2_HUMANRAB38_HUMANIntAct32814053 details
MECP2_HUMANCYFP1_HUMANIntAct32814053 details
MECP2_HUMANDDX20_HUMANIntAct32814053 details
MECP2_HUMANRASF1_HUMANIntAct32814053 details
MECP2_HUMANKAT5_HUMANIntAct32814053 details
MECP2_HUMANIQEC1_HUMANIntAct32814053 details
MECP2_HUMANSTX11_HUMANIntAct32814053 details
MECP2_HUMANPIAS1_HUMANIntAct32814053 details
MECP2_HUMANCSN3_HUMANIntAct32814053 details
MECP2_HUMANRN112_HUMANIntAct32814053 details
MECP2_HUMANBRK1_HUMANIntAct32814053 details
MECP2_HUMANTHIO_HUMANIntAct32814053 details
MECP2_HUMANSMN_HUMANIntAct32814053 details
MECP2_HUMANSNF5_HUMANBioGRID, HPRD, IntAct1569166 15696166 32814053 details
MECP2_HUMANNP1L3_HUMANIntAct32814053 details
MECP2_HUMANMSH5_HUMANIntAct32814053 details
MECP2_HUMANLYN_HUMANIntAct32814053 details
MECP2_HUMANEYA3_HUMANIntAct32814053 details
MECP2_HUMANCTNB1_HUMANIntAct32814053 details
MECP2_HUMANTRI74_HUMANIntAct32814053 details
MECP2_HUMANSPT12_HUMANIntAct32814053 details
MECP2_HUMANKRA81_HUMANIntAct32814053 details
MECP2_HUMANFOXR1_HUMANIntAct32814053 details
MECP2_HUMANTRI69_HUMANIntAct32814053 details
MECP2_HUMANRN183_HUMANIntAct32814053 details
MECP2_HUMANATIF1_HUMANIntAct32814053 details
MECP2_HUMANHUMMR_HUMANIntAct32814053 details
MECP2_HUMANNFL_HUMANIntAct32814053 details
MECP2_HUMANPRPS1_HUMANIntAct32814053 details
MECP2_HUMANWFS1_HUMANIntAct32814053 details
MECP2_HUMANOPTN_HUMANIntAct32814053 details
MECP2_HUMANHD_HUMANIntAct32814053 details
MECP2_HUMANPR40A_HUMANBioGRID, HPRD14618241 9171351 details
MECP2_HUMANHMGB1_HUMANBioGRID, HPRD11748221 details
MECP2_HUMANSKI_HUMANBioGRID, HPRD11441023 details
MECP2_HUMANNCOR1_HUMANBioGRID, HPRD11441023 28348241 details
MECP2_HUMANTF2B_HUMANBioGRID10756192 details
MECP2_HUMANH32_HUMANBioGRID12427740 21278419 details
MECP2_HUMANDNMT1_HUMANBioGRID12473678 details
MECP2_HUMANHDAC1_HUMANBioGRID12473678 14593184 14647463 16331260 details
MECP2_HUMANPR40B_HUMANBioGRID14618241 details
MECP2_HUMANSPI1_HUMANBioGRID14647463 16331260 details
MECP2_HUMANLBR_HUMANBioGRID19331822 details
MECP2_HUMANCDKL5_HUMANBioGRID15917271 details
MECP2_HUMANTYY1_HUMANBioGRID20504995 24981860 details
MECP2_HUMANRNF4_HUMANBioGRID25355316 29180619 details
MECP2_HUMANDNM3L_HUMANBioGRID24952347 details
MECP2_HUMANTBL1X_HUMANBioGRID28348241 details
MECP2_HUMANATRX_HUMANDIP17296936 details
MECP2_HUMANSUH_HUMANBioGRID, MINT16763620 25609649 details
MECP2_HUMANRCOR1_HUMANBioGRID12399542 details
MECP2_HUMANSUV91_HUMANBioGRID12399542 details
MECP2_HUMANSP1_HUMANBioGRID15109260 20385708 details
MECP2_HUMANSMCE1_HUMANBioGRID15696166 details
MECP2_HUMANCBX5_HUMANBioGRID17698499 22615490 details
MECP2_HUMANYBOX1_HUMANBioGRID16251272 22615490 details
MECP2_HUMANSP3_HUMANBioGRID20385708 details
MECP2_HUMANSOX2_HUMANBioGRID20368621 details
MECP2_HUMANTERF2_HUMANBioGRID20811636 details
MECP2_HUMANSMC3_HUMANBioGRID22615490 details
MECP2_HUMANCBX1_HUMANBioGRID22615490 details
MECP2_HUMANCBX3_HUMANBioGRID22615490 34079125 details
MECP2_HUMANH2A2C_HUMANBioGRID21278419 details
MECP2_HUMANH2B2E_HUMANBioGRID21278419 details
MECP2_HUMANH4_HUMANBioGRID21278419 30804502 details